Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Osr Holdings Inc (OSRH)

Osr Holdings Inc (OSRH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch PR Newswire - Thu Jan 22, 8:55AM CST

BELLEVUE, Wash. , Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's...

OSRH : 0.5565 (-3.87%)
Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform PR Newswire - Fri Jan 16, 8:20AM CST

BELLEVUE, Wash. , Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien...

OSRH : 0.5565 (-3.87%)
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones PR Newswire - Mon Jan 12, 7:05AM CST

BELLVUE, Wash. , Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe...

OSRH : 0.5565 (-3.87%)
Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR Newswire - Fri Dec 19, 2025

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university

OSRH : 0.5565 (-3.87%)
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement Newsfile - Thu Dec 4, 2025

New York, New York--(Newsfile Corp. - December 4, 2025) - Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and 12-month price...

OSRH : 0.5565 (-3.87%)
OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire - Mon Dec 1, 2025

BELLEVUE, Wash. , Dec. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced...

OSRH : 0.5565 (-3.87%)
Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones PR Newswire - Fri Nov 21, 2025

BELLEVUE, Wash. , Nov. 21, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"),...

OSRH : 0.5565 (-3.87%)
OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion PR Newswire - Fri Nov 14, 2025

BELLEVUE, Wash. , Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific...

OSRH : 0.5565 (-3.87%)
OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study PR Newswire - Thu Nov 6, 2025

BELLEVUE, Wash. , Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration...

OSRH : 0.5565 (-3.87%)
Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target Newsfile - Mon Oct 20, 2025

New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month...

OSRH : 0.5565 (-3.87%)

Barchart Exclusives

Oracle Is Selling $20 Billion in Common Stock. What Does That Mean for ORCL, and Should You Buy Shares Now? Barchart - 1 minute ago
Oracle’s $20 billion stock sale aims to fund its AI-driven cloud expansion, and this article examines what the move means for the company and whether investors should consider buying ORCL shares right now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot